KR102605759B1 - Pde1 억제제로서의 이미다조피라지논 - Google Patents

Pde1 억제제로서의 이미다조피라지논 Download PDF

Info

Publication number
KR102605759B1
KR102605759B1 KR1020177030665A KR20177030665A KR102605759B1 KR 102605759 B1 KR102605759 B1 KR 102605759B1 KR 1020177030665 A KR1020177030665 A KR 1020177030665A KR 20177030665 A KR20177030665 A KR 20177030665A KR 102605759 B1 KR102605759 B1 KR 102605759B1
Authority
KR
South Korea
Prior art keywords
methyl
imidazo
pyrazin
pyran
tetrahydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177030665A
Other languages
English (en)
Korean (ko)
Other versions
KR20170140216A (ko
Inventor
얀 켈레르
라르스 퀸 라스무센
모르텐 랑고르
미켈 예싱
파울로 호르헤 비에이라 비탈
카르스텐 율
Original Assignee
하. 룬드벡 아크티에셀스카브
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 하. 룬드벡 아크티에셀스카브 filed Critical 하. 룬드벡 아크티에셀스카브
Publication of KR20170140216A publication Critical patent/KR20170140216A/ko
Application granted granted Critical
Publication of KR102605759B1 publication Critical patent/KR102605759B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020177030665A 2015-04-30 2016-04-29 Pde1 억제제로서의 이미다조피라지논 Active KR102605759B1 (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
DKPA201500261 2015-04-30
DKPA201500261 2015-04-30
DKPA201500666 2015-10-29
DKPA201500666 2015-10-29
DKPA201600202 2016-04-04
DKPA201600202 2016-04-04
PCT/EP2016/059583 WO2016174188A1 (en) 2015-04-30 2016-04-29 Imidazopyrazinones as pde1 inhibitors

Publications (2)

Publication Number Publication Date
KR20170140216A KR20170140216A (ko) 2017-12-20
KR102605759B1 true KR102605759B1 (ko) 2023-11-23

Family

ID=55910242

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177030665A Active KR102605759B1 (ko) 2015-04-30 2016-04-29 Pde1 억제제로서의 이미다조피라지논

Country Status (42)

Country Link
US (4) US20160318939A1 (enExample)
EP (1) EP3288944B1 (enExample)
JP (1) JP6663930B2 (enExample)
KR (1) KR102605759B1 (enExample)
CN (1) CN107531714B (enExample)
AU (1) AU2016256573B2 (enExample)
BR (1) BR112017023182B1 (enExample)
CA (1) CA2983563A1 (enExample)
CL (1) CL2017002719A1 (enExample)
CO (1) CO2017010399A2 (enExample)
CY (1) CY1121806T1 (enExample)
DK (1) DK3288944T3 (enExample)
DO (1) DOP2017000254A (enExample)
EA (1) EA031946B1 (enExample)
EC (1) ECSP17072228A (enExample)
ES (1) ES2735422T3 (enExample)
GE (1) GEP20207058B (enExample)
GT (1) GT201700223A (enExample)
HK (1) HK1252098B (enExample)
HR (1) HRP20191180T1 (enExample)
HU (1) HUE044244T2 (enExample)
IL (1) IL255316B (enExample)
JO (1) JO3627B1 (enExample)
LT (1) LT3288944T (enExample)
MA (1) MA41977B1 (enExample)
ME (1) ME03414B (enExample)
MX (1) MX375737B (enExample)
MY (1) MY182382A (enExample)
PE (1) PE20180121A1 (enExample)
PH (1) PH12017501990B1 (enExample)
PL (1) PL3288944T3 (enExample)
PT (1) PT3288944T (enExample)
RS (1) RS59051B1 (enExample)
RU (1) RU2712219C2 (enExample)
SG (1) SG11201708822PA (enExample)
SI (1) SI3288944T1 (enExample)
SM (1) SMT201900393T1 (enExample)
TN (1) TN2017000428A1 (enExample)
TW (1) TWI695838B (enExample)
UA (1) UA123050C2 (enExample)
WO (1) WO2016174188A1 (enExample)
ZA (1) ZA201706847B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201629064A (zh) 2014-10-10 2016-08-16 H 朗德貝克公司 作爲pde1抑制劑之三唑並吡酮
JO3627B1 (ar) 2015-04-30 2020-08-27 H Lundbeck As إيميدازو بيرازينونات على هيئة مثبطات pde1
TWI729109B (zh) 2016-04-12 2021-06-01 丹麥商H 朗德貝克公司 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮
EP3529250B1 (en) 2016-10-18 2023-12-06 H. Lundbeck A/S Imidazopyrazinones, pyrazolopyrimidinones and pyrazolopyridinones as pde1 inhibitors
WO2018078042A1 (en) 2016-10-28 2018-05-03 H. Lundbeck A/S Combination treatments comprising administration of imidazopyrazinones
HUE050403T2 (hu) 2016-10-28 2020-12-28 H Lundbeck As Imidazopirazinonokkal végzett kombinációs kezelések pszichiátriai és/vagy kognitív betegségek kezelésére
JOP20190126A1 (ar) 2016-12-22 2019-05-28 H Lundbeck As بيرازولو [3، 4-b] بيريدينات وإيميدازو [1، 5-b] بيريدازينات على هيئة مثبطات PDE1
EP3562828A1 (en) 2016-12-28 2019-11-06 Dart NeuroScience LLC Substituted pyrazolopyrimidinone compounds as pde2 inhibitors
WO2019104285A1 (en) 2017-11-27 2019-05-31 Dart Neuroscience, Llc Substituted furanopyrimidine compounds as pde1 inhibitors
AR113926A1 (es) * 2017-12-14 2020-07-01 H Lundbeck As Derivados de 1h-pirazolo[4,3-b]piridinas
CN117447475A (zh) 2017-12-20 2024-01-26 H.隆德贝克有限公司 作为PDE1抑制剂的吡唑并[4,3-b]吡啶和咪唑并[1,5-a]嘧啶
US20210205310A1 (en) 2018-05-25 2021-07-08 Intra-Cellular Therapies, Inc. Organic compounds
IT202200024948A1 (it) * 2022-12-05 2024-06-05 Angelini Pharma S P A Composti attivatori dei canali potassio KV7.2/KV7.3

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080194592A1 (en) 2005-08-23 2008-08-14 Intra-Cellular Therapies, Inc. Organic Compounds
US20110281832A1 (en) 2008-12-06 2011-11-17 Peng Li Organic compounds
WO2013053690A1 (en) 2011-10-10 2013-04-18 H. Lundbeck A/S Pde9i with imidazo pyrazinone backbone
JP2013166727A (ja) 2012-02-16 2013-08-29 Dainippon Sumitomo Pharma Co Ltd ジヒドロイミダゾピラジノン誘導体

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB973361A (en) 1960-05-11 1964-10-28 Ciba Ltd Pyrazolo-pyrimidines and process for their manufacture
DE19709877A1 (de) 1997-03-11 1998-09-17 Bayer Ag 1,5-Dihydro-pyrazolo[3,4-d]-pyrimidinon-derivate
MY144532A (en) 2001-08-20 2011-09-30 Lundbeck & Co As H Novel method for down-regulation of amyloid
DE10238723A1 (de) 2002-08-23 2004-03-11 Bayer Ag Phenyl-substituierte Pyrazolyprimidine
DE10238722A1 (de) 2002-08-23 2004-03-11 Bayer Ag Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse
DE10238724A1 (de) 2002-08-23 2004-03-04 Bayer Ag Alkyl-substituierte Pyrazolpyrimidine
AU2004235915B2 (en) 2003-05-09 2010-08-05 Boehringer Ingelheim International Gmbh 6-cyclylmethyl- and 6-alkylmethyl-substituted pyrazolopyrimidines
ES2652440T3 (es) * 2004-04-02 2018-02-02 OSI Pharmaceuticals, LLC Inhibidores de proteína cinasa heterobicíclicos sustituidos con anillo 6,6-bicíclico
US7872124B2 (en) * 2004-12-21 2011-01-18 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US8012936B2 (en) 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
JP5837278B2 (ja) 2006-12-05 2015-12-24 イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. 新規使用
PT2152712E (pt) 2007-05-11 2012-02-29 Pfizer Compostos amino-heterocíclicos
US20090143391A1 (en) 2007-11-30 2009-06-04 Norbert Hofgen Aryl and heteroaryl fused imidazo [1,5-a] pyrazines as inhibitors of phosphodiesterase 10
UA105362C2 (en) 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
BRPI0918527A2 (pt) 2008-09-08 2015-12-01 Boehring Ingelheim Internat Gmbh compostos para o tratamento de disturbios do cns
EA201170768A1 (ru) * 2008-12-06 2012-05-30 Интра-Селлулар Терапиз, Инк. Органические соединения
TWI404721B (zh) 2009-01-26 2013-08-11 Pfizer 胺基-雜環化合物
EP2440234A4 (en) 2009-06-10 2013-11-06 Univ New York IMMUNOLOGICAL AIMING OF PATHOLOGICAL TAU PROTEINS
US9434730B2 (en) 2010-05-31 2016-09-06 Intra-Cellular Therapies, Inc. PDE1 inhibitor compounds
PT3042917T (pt) 2010-08-12 2018-05-02 Lilly Co Eli Anticorpos do péptido beta amilóide anti-n3pglu e seus usos
EP3181566A1 (en) * 2010-09-20 2017-06-21 Ironwood Pharmaceuticals, Inc. Imidazotriazinone compounds
EP2619204A4 (en) 2010-09-21 2014-08-27 Merck Sharp & Dohme TRIAZOLOPYRAZINONE AS P2X7 RECEPTOR ANTAGONISTS
JO3089B1 (ar) 2010-11-19 2017-03-15 H Lundbeck As مشتقات ايميدازول كمثبطات لانزيمات pde10a
US9499610B2 (en) 2011-04-08 2016-11-22 H. Lundbeck A/S Antibodies specific to pyroglutamated Aβ
JP6051210B2 (ja) 2011-06-10 2016-12-27 イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. 有機化合物
HK1199879A1 (en) 2012-01-26 2015-07-24 H.隆德贝克有限公司 Pde9 inhibitors with imidazo triazinone backbone
US9499562B2 (en) 2012-06-18 2016-11-22 Dart Neuroscience (Cayman) Ltd. Substituted thiophene- and furan-fused azolopyrimidine-5-(6H)-one compounds
ES2836129T3 (es) 2013-03-15 2021-06-24 Intra Cellular Therapies Inc Compuestos orgánicos
JP5783297B2 (ja) 2013-08-06 2015-09-24 株式会社デンソー 力学量センサ
AP2016009370A0 (en) 2014-02-19 2016-08-31 H Lundbeck As 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease
JP5797815B1 (ja) 2014-06-27 2015-10-21 細田建設株式会社 後施工アンカー及びその施工方法
US20160083391A1 (en) 2014-09-18 2016-03-24 Sunovion Pharmaceuticals Inc. Tricyclic piperazine derivative
US20170273985A1 (en) 2014-09-18 2017-09-28 Sunovion Pharmaceuticals Inc. Tricyclic derivative
US20160083400A1 (en) 2014-09-18 2016-03-24 Sunovion Pharmaceuticals Inc. Tricyclic guanidine derivative
TW201629064A (zh) 2014-10-10 2016-08-16 H 朗德貝克公司 作爲pde1抑制劑之三唑並吡酮
MA40941A (fr) 2014-11-10 2017-09-19 H Lundbeck As 2-amino-5,5-difluoro-6-(fluorométhyl)-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1
JO3458B1 (ar) 2014-11-10 2020-07-05 H Lundbeck As 2- أمينو-6- (دايفلوروميثيل) – 5، 5- ديفلورو-6-فينيل-3،4، 5، 6-تيتراهيدروبيريدين كمثبطات bace1
CR20170187A (es) 2014-11-10 2018-02-01 H Lundbeck As 2-Amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de BACE1 para el tratamiento de la enfermedad de Alzheimer
US20180044343A1 (en) 2015-03-16 2018-02-15 Sumitomo Dainippon Pharma Co., Ltd. Bicyclic imidazolo derivative
TW201643167A (zh) 2015-04-22 2016-12-16 H 朗德貝克公司 作爲pde1抑制劑之咪唑並三酮
JO3627B1 (ar) 2015-04-30 2020-08-27 H Lundbeck As إيميدازو بيرازينونات على هيئة مثبطات pde1
JO3711B1 (ar) 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
CA2993630A1 (en) 2015-08-12 2017-02-16 H. Lundbeck A/S 2-amino-3-fluoro-3-(fluoromethyl)-6-methyl-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors
TWI609870B (zh) 2016-02-12 2018-01-01 美國禮來大藥廠 Pde1抑制劑
TWI729109B (zh) 2016-04-12 2021-06-01 丹麥商H 朗德貝克公司 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮
EP3529250B1 (en) 2016-10-18 2023-12-06 H. Lundbeck A/S Imidazopyrazinones, pyrazolopyrimidinones and pyrazolopyridinones as pde1 inhibitors
HUE050403T2 (hu) 2016-10-28 2020-12-28 H Lundbeck As Imidazopirazinonokkal végzett kombinációs kezelések pszichiátriai és/vagy kognitív betegségek kezelésére
WO2018078042A1 (en) 2016-10-28 2018-05-03 H. Lundbeck A/S Combination treatments comprising administration of imidazopyrazinones

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080194592A1 (en) 2005-08-23 2008-08-14 Intra-Cellular Therapies, Inc. Organic Compounds
US20110281832A1 (en) 2008-12-06 2011-11-17 Peng Li Organic compounds
WO2013053690A1 (en) 2011-10-10 2013-04-18 H. Lundbeck A/S Pde9i with imidazo pyrazinone backbone
JP2013166727A (ja) 2012-02-16 2013-08-29 Dainippon Sumitomo Pharma Co Ltd ジヒドロイミダゾピラジノン誘導体

Also Published As

Publication number Publication date
ECSP17072228A (es) 2018-02-28
MX375737B (es) 2025-03-06
PE20180121A1 (es) 2018-01-18
US10858362B2 (en) 2020-12-08
TWI695838B (zh) 2020-06-11
HK1252098B (en) 2020-02-07
US11472810B2 (en) 2022-10-18
TW201700477A (zh) 2017-01-01
EA031946B1 (ru) 2019-03-29
CA2983563A1 (en) 2016-11-03
BR112017023182A2 (enExample) 2018-10-02
RU2712219C2 (ru) 2020-01-27
JP6663930B2 (ja) 2020-03-13
ME03414B (me) 2020-01-20
ES2735422T3 (es) 2019-12-18
HUE044244T2 (hu) 2019-10-28
PT3288944T (pt) 2019-07-19
CY1121806T1 (el) 2020-07-31
EP3288944A1 (en) 2018-03-07
DK3288944T3 (da) 2019-07-22
JO3627B1 (ar) 2020-08-27
HK1252098A1 (en) 2019-05-17
CO2017010399A2 (es) 2018-01-05
US10011606B2 (en) 2018-07-03
UA123050C2 (uk) 2021-02-10
WO2016174188A1 (en) 2016-11-03
SMT201900393T1 (it) 2019-09-09
MY182382A (en) 2021-01-22
HRP20191180T1 (hr) 2019-10-04
JP2018514552A (ja) 2018-06-07
KR20170140216A (ko) 2017-12-20
ZA201706847B (en) 2019-01-30
BR112017023182B1 (pt) 2023-10-31
SI3288944T1 (sl) 2019-08-30
IL255316A0 (en) 2017-12-31
EA201792157A1 (ru) 2018-03-30
LT3288944T (lt) 2019-07-25
US20160318939A1 (en) 2016-11-03
US20190062335A1 (en) 2019-02-28
PH12017501990B1 (en) 2021-01-13
TN2017000428A1 (en) 2019-04-12
MX2017013785A (es) 2018-03-27
AU2016256573B2 (en) 2019-11-21
MA41977A (fr) 2018-07-23
RU2017137514A (ru) 2019-05-31
CL2017002719A1 (es) 2018-04-20
PH12017501990A1 (en) 2018-03-26
US20170291903A1 (en) 2017-10-12
AU2016256573A1 (en) 2017-12-14
IL255316B (en) 2021-10-31
EP3288944B1 (en) 2019-06-12
US20210238182A1 (en) 2021-08-05
GT201700223A (es) 2018-12-19
PL3288944T3 (pl) 2019-11-29
RU2017137514A3 (enExample) 2019-07-17
DOP2017000254A (es) 2018-01-15
RS59051B1 (sr) 2019-08-30
CN107531714B (zh) 2019-07-19
SG11201708822PA (en) 2017-11-29
GEP20207058B (en) 2020-01-27
MA41977B1 (fr) 2019-08-30
CN107531714A (zh) 2018-01-02

Similar Documents

Publication Publication Date Title
KR102605759B1 (ko) Pde1 억제제로서의 이미다조피라지논
EP3532064B1 (en) Combination treatments comprising imidazopyrazinones for the treatment of psychiatric and/or cognitive disorders
US10912773B2 (en) Combinations comprising substituted imidazo[1,5-a]pyrazinones as PDE1 inhibitors
OA18771A (en) Imidazopyrazinones as PDE1 Inhibitors
HK40005946B (en) Combination treatments comprising imidazopyrazinones for the treatment of psychiatric and/or cognitive disorders
HK40005946A (en) Combination treatments comprising imidazopyrazinones for the treatment of psychiatric and/or cognitive disorders

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20171024

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210412

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230414

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20230825

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20231121

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20231121

End annual number: 3

Start annual number: 1

PG1601 Publication of registration